Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Eylea 40 mg/ml solution for injection in pre-filled syringe

Active Ingredient:
aflibercept
Company:  
Bayer plc See contact details
ATC code: 
S01LA05
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Audio/Video
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

EYLEA BRVO Patient Guide

Your guide to Eylea - for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO)

{pdf_link}

EYLEA CNV Patient Guide

Your guide to Eylea - for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV)

{pdf_link}

EYLEA CRVO Patient Guide

Your guide to Eylea - for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO)

{pdf_link}

EYLEA DMO Patient Guide

Your guide to Eylea - for the treatment of visual impairment due to diabetic macular oedema (DMO)

{pdf_link}

Eylea Prescriber Guide

{healthcare_pro_orange} For Healthcare Professionals

Prescriber guide to intravitreal injections with Eylea.

{pdf_link}

Eylea ROP Parent Caregiver Guide

Information for parents and caregivers – for the treatment of retinopathy of prematurity (ROP)

{pdf_link}

EYLEA WAMD Patient Guide

Your guide to Eylea - for the treatment of neovascular (wet) age-related macular degeneration (AMD).

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Bayer plc
Company image
Address
400 South Oak Way, Reading, Berkshire, RG2 6AD
Medical Information e-mail
[email protected]
WWW
http://www.bayer.co.uk
Telephone
+44 (0)118 206 3000